Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) insider Tsveta Milanova sold 2,770 shares of the firm's stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total value of $92,905.80. Following the completion of the sale, the insider now directly owns 26,122 shares of the company's stock, valued at approximately $876,131.88. This trade represents a 9.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Agios Pharmaceuticals Stock Performance
NASDAQ AGIO traded up $0.94 during trading hours on Thursday, reaching $33.65. The company's stock had a trading volume of 274,744 shares, compared to its average volume of 653,135. The company's 50-day moving average is $31.03 and its two-hundred day moving average is $32.38. Agios Pharmaceuticals, Inc. has a fifty-two week low of $23.42 and a fifty-two week high of $62.58. The stock has a market cap of $1.95 billion, a PE ratio of 2.99 and a beta of 0.73.
Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The biopharmaceutical company reported ($1.55) EPS for the quarter, beating the consensus estimate of ($1.80) by $0.25. Agios Pharmaceuticals had a net margin of 1,798.26% and a negative return on equity of 2.75%. The business had revenue of $8.73 million for the quarter, compared to analyst estimates of $9.86 million. Equities analysts expect that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of equities analysts have recently issued reports on the stock. Scotiabank cut their price target on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a report on Friday, May 2nd. Wall Street Zen cut shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Monday, May 19th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $58.60.
View Our Latest Analysis on Agios Pharmaceuticals
Institutional Investors Weigh In On Agios Pharmaceuticals
Institutional investors and hedge funds have recently bought and sold shares of the stock. Envestnet Asset Management Inc. raised its holdings in shares of Agios Pharmaceuticals by 3.3% in the fourth quarter. Envestnet Asset Management Inc. now owns 24,805 shares of the biopharmaceutical company's stock worth $815,000 after acquiring an additional 795 shares during the last quarter. GAMMA Investing LLC boosted its stake in shares of Agios Pharmaceuticals by 9,296.6% during the first quarter. GAMMA Investing LLC now owns 8,175 shares of the biopharmaceutical company's stock valued at $240,000 after acquiring an additional 8,088 shares during the last quarter. Venturi Wealth Management LLC purchased a new stake in Agios Pharmaceuticals during the 4th quarter worth about $33,000. Vanguard Group Inc. increased its position in Agios Pharmaceuticals by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company's stock worth $185,045,000 after purchasing an additional 85,339 shares in the last quarter. Finally, Northern Trust Corp raised its stake in Agios Pharmaceuticals by 0.9% in the 4th quarter. Northern Trust Corp now owns 595,480 shares of the biopharmaceutical company's stock valued at $19,567,000 after purchasing an additional 5,372 shares during the last quarter.
About Agios Pharmaceuticals
(
Get Free Report)
Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Agios Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agios Pharmaceuticals wasn't on the list.
While Agios Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
